Introduction:A case control study with a sample size 117 of patients with COVID-19 infection were investigated in order to examine the benefit of usage of anticoagulants in a retrospective manner in the state of Florida. Recently, researchers found that COVID-19 is associated with a higher incidence of thrombosis than the general population. There are various mechanisms proposed for thrombosis development, most of which are still not fully understood. The addition of anticoagulants during treatment for COVID revealed a significant mortality benefit, about 8% died in the case group including 80% of whom did not receive anticoagulant. In contrast, 37% died in the control group, 4 (80%) out of 5 patients who survived were already on anticoagulants prior to the admission. A significant P value has been seen with 0.0001, OR 41.2 and CI 95%.
Background and objective: The aim of the study is to assess the fundamental roles of anticoagulants in treatment of COVID-19 patients and an improvement of the survival rate. The goal is to provide statistical evidence that anticoagulants correlate with an improvement of the survival rate and reduce the hospitalization.
Method: Case-Control Study was conducted in COVID-19 patients and admitted to hospital. The data was obtained from two different hospitals in Florida for the year 2020-2021. Total of 117 patients were included in the study and were assigned to either the case group or the control group. In the case group; there were 65 patients versus 52 patients in the control group.
Results: In one hundred seventeen patients, 53 out of 65 patients in the case group received anticoagulants, while only 5 out of 52 in the control group were already on anticoagulants secondary to medical conditions. Additionally, 24 patients died, however only 5 out of 65 patients in the case group versus 19 out of 52 in the control group, such implementation suggests a decrease in mortality rate with the use of anticoagulants.
Conclusion: The usage of anticoagulants in COVID-19 patients provided a drastic decline in mortality rate and reduced hospitalization.
Under Processing (Review Completed)
Received date: August 10, 2021
Accepted date: 2021
Published date: 2021
©2021 Hussain HH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hussain HH (2021) The Adjunctive Advantage of Using Implications of Anticoagulants in Decreasing the Mortality in Patients with COVID-19 Infection: A Case-control Study. OSP J Health Car Med 2:
2310 Dolan Falls LN, Houston, TX, USA, 77089. email@example.com